1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Seven Clinical Trial Read-Outs Due In Q4

 
• By Alexandra Shimmings

The last three months of the year should see data reporting from a number of key studies for novel products including Roche's emicizumab. Scrip takes a look at some of the more interesting studies expected by year end, with the help of analysts from Informa's Biomedtracker.

Testing
Clinical Trial Read-Outs • Source: Shutterstock

Catalyst: Phase III VITALITY top-line results

Biomedtracker's LOA Opinion*: Below

*Biomedtracker’s proprietary rating of the likelihood of approval of a particular drug, in comparison to average approval rates for drugs in that class

Thanks to funding from the ALS Association's Ice Bucket Challenge and a partnership with Astellas Pharma Inc., Cytokinetics Inc. pursued Phase III development of its fast skeletal muscle troponin activator in amyotrophic lateral sclerosis (ALS) despite its failure in the Phase IIb BENEFTI-ALS study in 2014. (Also see "Cytokinetics plunges as tirasemtiv fails to BENEFIT-ALS" - Scrip, 26 April, 2014.)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Lilly’s Orforglipron Makes Strong Showing In Diabetic Obesity Population

 
• By Alaric DeArment

The drugmaker announced topline results from the Phase III ATTAIN-2 trial in overweight/obese patients with type 2 diabetes and plans to file for approval.

Regeneron Plans To File Cemdisiran For gMG But Will Face Tough Market

 
• By Jessica Merrill

Head of hematology clinical development Andres Sirulnik talked to Scrip about the positive Phase III results for the siRNA medicine.

Pipeline Watch: Twelve Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Argenx’s Vyvgart Positioned For Broadest Label In Myasthenia Gravis

 
• By Jessica Merrill

The company reported positive Phase III data in individuals with gMG who are ACHr-Ab seronegative, providing an expansion opportunity.

More from R&D

Pipeline Watch: Twelve Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Argenx’s Vyvgart Positioned For Broadest Label In Myasthenia Gravis

 
• By Jessica Merrill

The company reported positive Phase III data in individuals with gMG who are ACHr-Ab seronegative, providing an expansion opportunity.

Pipeline-In-A-Product: A Retrospective On The Development Of Dupixent

 
• By Jessica Merrill, Kevin Grogan, and Edwin Elmhirst

Dupixent’s success across eight indications is a model other drugmakers would like to replicate. R&D leaders at Sanofi and Regeneron reflect back on the development strategy that built the $15bn product.